Ambitious challenges demand pioneering collaborations

a--up

none

a--up

none

a--up

none

At Isomorphic Labs, our mission is to solve all disease. An ambitious goal, certainly. And one we know we’ll only be able to achieve with the right team, the right technology, and the right partners.

Our culture of collaboration extends beyond the walls of our offices and underpins every one of our relationships - whether you’re a pharmaceutical company, a biotech, a CRO, or another important pioneering player.

Together we are turning the promise of digital biology into meaningful proof. With breakthrough technology and biomedical expertise, we are ushering in a new era of therapeutic development to improve and extend the lives of millions of people.

And not a moment too soon.

a--up

none

Novartis

a--up

none

Details of our partnership

We first announced a strategic research collaboration with Novartis, an established leader in the creation of innovative medicines, in January 2024. Reflecting the progress made in just over one year of working together, Iso and Novartis announced an expansion of our partnership in February 2025.

The initial scope of our research collaboration was focused on the discovery of small molecule therapeutics against three particularly challenging targets. That has now been expanded - adding up to three additional research programs.

a--up

none

FIONA MARSHALL, PRESIDENT OF BIOMEDICAL RESEARCH AT NOVARTIS

a--up

none

“Over the past year, we have witnessed the exploration of new chemical spaces that would be unavailable to probe through traditional methods, and I look forward to continuing our work together on additional difficult targets with the potential to address significant unmet patient needs.”

a--up

none

Eli Lilly

a--up

none

Details of our partnership

Iso’s strategic research collaboration with Eli Lilly and Company reflects our shared commitment to advancing groundbreaking drug design through the application of cutting-edge science.

The partnership is focused on discovering small molecule therapeutics against a number of undisclosed targets.

a--up

none

Our partnership principles

a--up

none

Synergy

Each of our partners bring their own strengths and domain expertise to our collaborations. When combined with Isomorphic Labs’ unique capabilities, we accelerate toward the creation of new and needed medicines.

a--up

none

Collaboration

True innovation in drug discovery requires deep, continuous collaboration. By working closely with our partners, we bridge the gap between advanced AI and real-world medical challenges - aligning expertise, sharing insights and refining approaches together.

a--up

none

Urgency

Science has been frustrated by too many intractable diseases for far too long. Our partnerships amplify the intensity with which we can attack challenging targets, and accelerate toward meaningful therapeutic breakthroughs.

a--up

none

Impact

The scale of the challenge is enormous. So is the opportunity. Our partnerships unite us in the pursuit of our shared goal: to develop medicines for those who need them most.